Cover Image

Efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated falciparum malaria: a controlled trial in Burkina Faso

Objective To assess the efficacy of methylene blue (MB) monotherapy in semi-immune adults with uncomplicated malaria in Burkina Faso. Methods In an open-label controlled phase II study with 60 semi-immune adults with uncomplicated falciparum malaria in Nouna, north-western Burkina Faso, MB monothera...

Full description

Saved in:
Bibliographic Details
Main Authors: Bountogo, Mamadou (Author) , Zoungrana, Augustin (Author) , Coulibaly, Boubacar (Author) , Klose, Christina (Author) , Mansmann, Ulrich (Author) , Mockenhaupt, Frank P. (Author) , Burhenne, Jürgen (Author) , Mikus, Gerd (Author) , Walter-Sack, Ingeborg (Author) , Schirmer, Rolf Heiner (Author) , Sié, Ali (Author) , Meissner, Peter (Author) , Müller, Olaf (Author)
Format: Article (Journal)
Language:English
Published: 10 May 2010
In: Tropical medicine & international health
Year: 2010, Volume: 15, Issue: 6, Pages: 713-717
ISSN:1365-3156
DOI:10.1111/j.1365-3156.2010.02526.x
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1111/j.1365-3156.2010.02526.x
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-3156.2010.02526.x
Get full text
Author Notes:Mamadou Bountogo, Augustin Zoungrana, Boubacar Coulibaly, Christina Klose, Ulrich Mansmann, Frank P. Mockenhaupt, Jürgen Burhenne, Gerd Mikus, Ingeborg Walter-Sack, R. Heiner Schirmer, Ali Sié, Peter Meissner, and Olaf Müller
Description
Summary:Objective To assess the efficacy of methylene blue (MB) monotherapy in semi-immune adults with uncomplicated malaria in Burkina Faso. Methods In an open-label controlled phase II study with 60 semi-immune adults with uncomplicated falciparum malaria in Nouna, north-western Burkina Faso, MB monotherapy (390 mg twice daily) was given sequentially to groups of 20 adults for 7 days (MB7), 5 days (MB5) and 3 days (MB3), respectively. The primary outcome was the rate of adequate clinical and parasitological response (ACPR) on day 28 of follow-up. Results Of the study population, 27/58 (47%) and 5/51 (10%) patients still had parasites on days 2 and 3, respectively, of follow-up resulting in 9/58 (16%) early treatment failures. By day 14, no recrudescence was observed but in 4/19 (MB5) and 2/20 (MB3) individuals by day 28. The PCR-corrected rate of ACPR was 72%, 58% and 85% in groups 7, 5 and 3, respectively, by per protocol analysis. Self-limiting dysuria was the most frequent adverse event. Conclusions MB acts slowly against the blood stages of P. falciparum. MB alone needs to be given for at least 7 days to be efficacious in the treatment of falciparum malaria but should be used in combination with a fast acting antimalarial.
Item Description:Gesehen am 15.02.2023
Physical Description:Online Resource
ISSN:1365-3156
DOI:10.1111/j.1365-3156.2010.02526.x

Similar Items